Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro

J Cell Biol. 1990 Aug;111(2):743-55. doi: 10.1083/jcb.111.2.743.

Abstract

Tightly controlled proteolytic degradation of the extracellular matrix by invading microvascular endothelial cells is believed to be a necessary component of the angiogenic process. We have previously demonstrated the induction of plasminogen activators (PAs) in bovine microvascular endothelial (BME) cells by three agents that induce angiogenesis in vitro: basic FGF (bFGF), PMA, and sodium orthovanadate. Surprisingly, we find that these agents also induce plasminogen activator inhibitor-1 (PAI-1) activity and mRNA in BME cells. We also find that transforming growth factor-beta 1 (TGF-beta 1), which in vitro modulates a number of endothelial cell functions relevant to angiogenesis, also increases both PAI-1 and urokinase-type PA (u-PA) mRNA. Thus, production of both proteases and protease inhibitors is increased by angiogenic agents and TGF-beta 1. However, the kinetics and amplitude of PAI-1 and u-PA mRNA induction by these agents are strikingly different. We have used the ratio of u-PA:PAI-1 mRNA levels as an indicator of proteolytic balance. This ratio is tilted towards enhanced proteolysis in response to bFGF, towards antiproteolysis in response to TGF-beta 1, and is similar to that in untreated cultures when the two agents are added simultaneously. Using an in vitro angiogenesis assay in three-dimensional fibrin gels, we find that TGF-beta 1 inhibits the bFGF-induced formation of tube-like structures, resulting in the formation of solid endothelial cell cords within the superficial parts of the gel. These results suggest that a net positive proteolytic balance is required for capillary lumen formation. A novel perspective is provided on the relationship between extracellular matrix invasion, lumen formation, and net proteolytic balance, thereby reflecting the interplay between angiogenesis-modulating cytokines such as bFGF and TGF-beta 1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Base Sequence
  • Cattle
  • Cells, Cultured
  • DNA / genetics
  • DNA / isolation & purification
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / physiology*
  • Enzyme Induction
  • Fibroblast Growth Factors / pharmacology*
  • Kinetics
  • Molecular Sequence Data
  • Neovascularization, Pathologic*
  • Peptide Hydrolases / genetics*
  • Plasminogen Activators / biosynthesis
  • Plasminogen Activators / genetics*
  • Plasminogen Inactivators*
  • Protein Precursors / genetics*
  • RNA, Messenger / genetics
  • Restriction Mapping
  • Tetradecanoylphorbol Acetate / pharmacology
  • Transcription, Genetic / drug effects*
  • Transforming Growth Factors / pharmacology*
  • Urokinase-Type Plasminogen Activator / biosynthesis
  • Urokinase-Type Plasminogen Activator / genetics*
  • Vanadates / pharmacology

Substances

  • Plasminogen Inactivators
  • Protein Precursors
  • RNA, Messenger
  • Vanadates
  • Fibroblast Growth Factors
  • Transforming Growth Factors
  • DNA
  • Peptide Hydrolases
  • Plasminogen Activators
  • Urokinase-Type Plasminogen Activator
  • Tetradecanoylphorbol Acetate

Associated data

  • GENBANK/X52906
  • GENBANK/X52907